Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-ISV-RO plus anti-PD-1 for advanced solid tumors
ChiCTR2100053870Phase 2Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- May 2021
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of rho(d) immune globulin in Nonhematologic neoplasms, sponsored by Nanjing Drum-Tower Hospital. Started May 2021; status: recruiting.
02
Drugs
rho(d) immune globulin
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2100053870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053870.